Navigation Links
Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Date:2/11/2008

BOULDER, Colo., and MONTREAL, Feb. 11 /PRNewswire-FirstCall/ -- Pharmion (Nasdaq: PHRM) and MethylGene Inc. (TSX: MYG) today announced that the European Medicines Agency (EMEA) and the European Commission (EC) designated MGCD0103, a histone deacetylase (HDAC) inhibitor, as an Orphan Medicinal Product for the treatment of acute myelogenous leukemia in the European Union (EU). Criteria for designation require that the product be intended for the treatment of life-threatening or serious conditions that are rare and affect not more than five in 10,000 persons in the EU.

Orphan Medicinal Product Designation allows special incentives for sponsors planning to test a product for use in a rare disease or condition generally characterized by a small number of patients. These incentives include eligibility for protocol assistance and possible exemptions or reductions of certain regulatory fees during development or at the time of application for marketing approval. Once approved, the product may qualify for 10 years of marketing exclusivity in the EU.

About MGCD0103

MGCD0103 is an orally-administered, isotype-selective HDAC inhibitor. The compound is currently in one Phase I combination clinical trial with Taxotere(R) for solid tumors, two Phase I/II combination trials with Vidaza(R) for hematological malignancies and with Gemzar(R) for pancreatic cancer, and five Phase II clinical trials in hematological malignancies.

MGCD0103 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of Hodgkin lymphoma and has been designated an Orphan Medicinal Product by the EMEA for the treatment of Hodgkin lymphoma and acute myelogenous leukemia.

About Acute Myelogenous Leukemia (
'/>"/>

SOURCE Pharmion Corporation; MethylGene Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
2. Pharmion and MethylGene Initiate Phase One Combination Clinical Trial with MGCD0103 and Taxotere(R) in Patients with Solid Tumors
3. Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
4. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
5. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
6. Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
7. Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
8. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... BUENA, N.J. , June 30, 2015  IGI ... Jersey based specialty generic pharmaceutical company, today ... application (ANDA) to the U.S. Food and Drug Administration ... of ANDA submissions now pending at the FDA to ... CEO of the Company, commented, "We believe our current ...
(Date:6/30/2015)... Millar, Inc. , a leader in catheter-based and wireless ... Craig Thummel , President/CEO and member of the ... the Company. The Company also announced its leadership succession ... Management team as his successors. The Board of Directors ... Sales and Marketing, as President, and also a member ...
(Date:6/30/2015)... June 30, 2015 A new analysis ... exposure to high-priced Hepatitis C medications could range ... percent of Californians infected with Hepatitis C receive treatment through ... of new Hepatitis C treatments on public programs, comes at ... price tags for drugs like Gilead Sciences, Harvoni and Sovaldi. ...
Breaking Medicine Technology:IGI Laboratories, Inc. Announces Fifth ANDA Submission Of 2015 2Millar, Inc. Announces Leadership Changes 2Millar, Inc. Announces Leadership Changes 3New Analysis Reveals High-Priced Hepatitis C Drugs Could Have Costly Impact on State 2New Analysis Reveals High-Priced Hepatitis C Drugs Could Have Costly Impact on State 3New Analysis Reveals High-Priced Hepatitis C Drugs Could Have Costly Impact on State 4
... Reportlinker.com announces that a new market research ... Commercial Insight: Antihormonal Cancer Therapies ... sales erosion http://www.reportlinker.com/p0255121/Commercial-Insight-Antihormonal-Cancer-Therapies---Leading-brands-strive-to-minimize-generic-sales-erosion.html ... are a class of drugs used predominantly ...
... Ind., Nov. 8, 2010 EXTENSION, INC . announced ... it will make available for general release to the healthcare ... existing offerings use Cisco IP devices and smartphones as end ... the smartphone devices will not only serve as communication end ...
Cached Medicine Technology:Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 2Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 3Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 4Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 5Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 6Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 7Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 8Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 9EXTENSION, INC. to Launch Apple iPhone Application for Use in Clinical Workflows 2EXTENSION, INC. to Launch Apple iPhone Application for Use in Clinical Workflows 3
(Date:7/1/2015)... ... , ... Franklin University, one of the leading educators of working adults in ... Dean of the College of Health & Public Administration . , ... and mission of Franklin University via curriculum planning, course scheduling, faculty staffing and development, ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... Author Francesca Camp wasn’t always ... into her lap, so too did her support of the practice; a terrible car accident ... In her new book, “Do I Need It ? (And What if I Do?): ...
(Date:7/1/2015)... , ... July 01, 2015 , ... Research published in ... (Peek) smartphone app to test eyesight was just as accurate as those from standard ... Hygiene and Tropical Medicine is responsible for the development of the test, which does ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... global distribution and marketing of a number of nutritional and beauty products, announced ... the 2015 ECRM Diet, Vitamin & Sports Nutrition conference in Tampa, Florida. This ...
(Date:7/1/2015)... ... , ... Nutritional Products International, a brand focused on the global marketing and ... ECRM Diet, Vitamin & Sports Nutrition conference in Tampa, Florida, where it made a ... show allows companies the chance to meet with a variety of the most influential ...
Breaking Medicine News(10 mins):Health News:Franklin University Appoints Dean of College of Health & Public Administration 2Health News:Francesca Camp’s New Book Unmasks Plastic Surgery Advice 2Health News:New Research Shows Reliability of Peek Eye Testing Mobile App 2Health News:New Research Shows Reliability of Peek Eye Testing Mobile App 3Health News:NPI Executives Report Great Success at ECRM Conference 2Health News:NPI Meets With Top Retail Figures at ECRM Conference 2
... unclear why it’s so, scientists at Johns Hopkins have linked ... tough//, protective casing that houses insects and worms to the ... ,A team of Hopkins sinus experts has found that the ... to 250 times more active in people with severe sinus ...
... say that there is nothing that matches gambling. Not even ... addict//. ,There has been an upsurge of gambling ... with gambling problems. According to some experts, this has led ... ,"It's related to other addictions, like alcoholism and tobacco addiction. ...
... may no longer be included in the specialist category, if ... ,A few radiologists who have had the opportunity ... them as part of the team. But the rest are ... physicians are unable to seek employment in breast clinics. And ...
... common man has seen a rapid increase in healthcare charges ... been affected not only by the rising cost of living// ... money-spinning business. ,The government in 2003 revised the ... had the benefit of ‘free’ hospital visits. In fact, they ...
... 10, sent a warning against dengue fever in the midst ... capital//. ,From this year’s January 1 to ... been reported, said the department. ,In order ... collaboration with the local officials of the affected areas, according ...
... and Drug Administration has charged the American Red Cross yet ... to the stipulation of safe blood collection techniques.// The Red ... the nation's requirement of blood, has been under the vigilance ... make the blood safe by enhancing the quality control system., ...
Cached Medicine News:Health News:Immune Response Linked to “Ghost” Parasites and Severely Congested Sinus 2Health News:Immune Response Linked to “Ghost” Parasites and Severely Congested Sinus 3Health News:Immune Response Linked to “Ghost” Parasites and Severely Congested Sinus 4Health News:Compulsive Gambling – a psychiatric disorde 2Health News:Escalating Healthcare charges in UAE 2Health News:Escalating Healthcare charges in UAE 3Health News:‘Search and Destroy’ operation against dengue mosquitoes in Philippin 2
... an OraSure HIV-1 Oral Specimen Collection Device is ... for HIV-1 antibodies. Testing with the OraSure HIV-1 ... needles and has been shown to be more ... specially treated cotton fiber pad attached to a ...
... benefits of TiMAX material have been applied to ... strength and an ultra-low profile combine to provide ... lower extremity. , ,This complete set of periarticular ... , Fibula Composite Plate , ...
The DePuy ACE Titanium Active Compression Plate offers ingenuity in the art of fracture management....
Corneal Marking Pen - Sterile. 10 pieces/box...
Medicine Products: